PROOF-HD Phase 3 Pridopidine Trial Reaches 25% Enrollment

PROOF-HD Phase 3 Pridopidine Trial Reaches 25% Enrollment

294997

PROOF-HD Phase 3 Pridopidine Trial Reaches 25% Enrollment

Prilenia Therapeutics has enrolled more than 120 patients in PROOF-HD, a Phase 3 clinical trial investigating the efficacy and safety of oral pridopidine in early stage Huntington’s disease. That amounts to 25% of the target enrollment of up to 480 patients, the company announced. The trial is ongoing at 60 sites in the U.S., Canada, and Europe. With those enrollment numbers, PROOF-HD (NCT04556656), conducted in collaboration with the Huntington Study Group, remains on track to complete…

You must be logged in to read/download the full post.